For the first time in four years, the FDA has approved a new prostate cancer drug for use in the United States. The new drug, degarelix, works similarly to some currently available drugs by blocking the effects of testosterone throughout the body.
The currently available drugs when first used, however, are known to cause a brief increase in testosterone levels before resulting in lower levels later on. Degarelix, has been shown not to cause this initial increase in testosterone.
With FDA approval secured, degarelix should be made widely available in the near future.